The tweet was deleted by the author.
But we saved everything 🙂.
Rigel Pharmaceuticals announced the completion of a global license agreement to develop, manufacture, and commercialize VEPPANU, also known as vepdegestrant.
The agreement marks a significant expansion in Rigel Pharmaceuticals product development pipeline, granting the company worldwide rights for VEPPANU. Further financial or strategic details of the partnership were not disclosed. VEPPANU, a next-generation therapy, is expected to advance Rigel Pharmaceuticals presence in the pharmaceutical sector. For more information, the company referred stakeholders to its official press release.
View post on X Loading...
Rigel Pharmaceuticals has continued to increase its focus on oncology, recently joining the ASCO Annual Meeting to discuss sector advancements at booth 33080, according to a company update published earlier. The company’s partner Kissei has also filed a new drug application in Japan for olutasidenib, targeting relapsed acute myeloid leukemia patients in a separate development. These steps reflect ongoing efforts to expand Rigel’s pipeline and global reach.